^
Association details:
| Biomarker: | HRAS mutation |
|---|---|
| Cancer: | Rhabdomyosarcoma |
| Drug: | Mekinist (trametinib) (MEK inhibitor) + Zarnestra (tipifarnib) (CXCL12 inhibitor, Farnesyl transferase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeting oncogenic HRAS in pediatric rhabdomyosarcoma
Published date:
10/12/2022
Excerpt:
We, therefore, tested tipifarnib in combination with trametinib in HRAS-mutant FN-RMS cell lines and observed additive dose-dependent 2D and 3D growth inhibition in response to the combination...Our data suggest that the combination of the FTI tipifarnib and the MEK inhibitor trametinib is active in models of HRAS-driven FN-RMS and may represent an effective therapeutic strategy for a genomically-defined subset of patients with FN-RMS.
